Pfizer Completes Licensing Agreement with 3SBio for Cancer Drug
Pfizer Inc has finalized a licensing agreement with 3SBio for the cancer drug SSGJ-707, granting Pfizer exclusive rights to develop and sell the medication. As a result of the agreement, 3SBio will receive a significant payment and Pfizer will make an equity investment in the company.
Terms of the Agreement
- Pfizer has acquired exclusive rights to develop and sell SSGJ-707
- 3SBio will receive a significant payment
- Pfizer will make an equity investment in 3SBio
Impact on Pfizer’s Business
The deal is expected to have a positive impact on Pfizer’s business, particularly in the oncology sector.
Stock Performance
Pfizer’s stock price has experienced fluctuations over the past year. Key statistics include:
- Recent surge of 8.24% over the past month
- Year-to-date loss reduced to 5.02%
- 8.75% decline over the past year
Recent Transactions
Pfizer has been involved in several recent transactions, including:
- 3SBio issuing 31.14 million shares to Pfizer, raising approximately 785 million Hong Kong dollars
- Sale of Pantera’s Smackover Project to Energy Exploration Technologies Inc. for A$40 million
Financial Impact
The sale of Pantera’s Smackover Project is expected to provide immediate capital and improve Pfizer’s financial position.
Overall Impact
Pfizer’s recent deals and transactions are expected to have a positive impact on the company’s business and financial performance.